Literature DB >> 10473093

The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue.

H Dotzlaw1, E Leygue, P Watson, L C Murphy.   

Abstract

The expression of PXR mRNA and a variant PXR mRNA, deleted in 111 nucleotides in the ligand-binding domain, was detected by reverse transcription-PCR amplification in both normal and neoplastic human breast tissues. The level of PXR mRNA did not differ between breast tumors and their adjacent matched normal breast tissues. However, the expression of PXR mRNA did vary among breast tumors. A statistically significant inverse relationship was found between the level of PXR mRNA expression and estrogen receptor (ER) status, as defined by ligand binding analysis. The level of PXR mRNA expression in ER+ tumors (median = 22.4, n = 15) was significantly lower (P = 0.04) than the level of PXR mRNA expression in ER-tumors (median = 46.7, n = 15). No relationship with progesterone receptor status was found. These data raise the possibility that PXR has a role in human breast tissues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473093

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

Review 1.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.

Authors:  Edith J Mensah-Osman; Dafydd G Thomas; Michelle M Tabb; Jose M Larios; Dennis P Hughes; Thomas J Giordano; Michelle L Lizyness; James M Rae; Bruce Blumberg; Paul F Hollenberg; Laurence H Baker
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

3.  Pregnane X Receptor-Humanized Mice Recapitulate Gender Differences in Ethanol Metabolism but Not Hepatotoxicity.

Authors:  Krisstonia Spruiell; Afua A Gyamfi; Susan T Yeyeodu; Ricardo M Richardson; Frank J Gonzalez; Maxwell A Gyamfi
Journal:  J Pharmacol Exp Ther       Date:  2015-07-09       Impact factor: 4.030

Review 4.  Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.

Authors:  Satyanarayana R Pondugula; Sridhar Mani
Journal:  Cancer Lett       Date:  2012-08-29       Impact factor: 8.679

Review 5.  Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism.

Authors:  Tomas Smutny; Lucie Hyrsova; Albert Braeuning; Magnus Ingelman-Sundberg; Petr Pavek
Journal:  Arch Toxicol       Date:  2020-11-09       Impact factor: 5.153

6.  Tumor suppressor protein p53 negatively regulates human pregnane X receptor activity.

Authors:  Ayesha Elias; Jing Wu; Taosheng Chen
Journal:  Mol Pharmacol       Date:  2013-03-27       Impact factor: 4.436

7.  A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response.

Authors:  Nico Scheer; Jillian Ross; Anja Rode; Branko Zevnik; Sandra Niehaves; Nicole Faust; C Roland Wolf
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

8.  Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression.

Authors:  Dione Gardner-Stephen; Jean-Marie Heydel; Amit Goyal; Yuan Lu; Wen Xie; Tim Lindblom; Peter Mackenzie; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2004-03       Impact factor: 3.922

9.  Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells.

Authors:  Suman Verma; Michelle M Tabb; Bruce Blumberg
Journal:  BMC Cancer       Date:  2009-01-05       Impact factor: 4.430

10.  PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line.

Authors:  Stefan Harmsen; I Meijerman; C L Febus; R F Maas-Bakker; J H Beijnen; J H M Schellens
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-30       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.